Dexi Bi
Impact in
- Molecular Medicine top 0.5%
- Antibiotic Resistance in Bacteria
- Endocrinology top 1%
- Vibrio bacteria research studies
Papers in
-
- Gut microbiota and health 8
- Genomics and Phylogenetic Studies 6
-
- Antibiotic Resistance in Bacteria 9
- Co-authors
- Hong‐Yu Ou (13 shared papers)Cui Tai (7 shared papers)Zixin Deng (6 shared papers)Kumar Rajakumar (7 shared papers)Yingzhou Xie (3 shared papers)Huiyuan Zhu (4 shared papers)Xinyi He (3 shared papers)Ewan M. Harrison (3 shared papers)
- Journals
- Nucleic Acids Research (4 papers)Antimicrobial Agents and Chemotherapy (3 papers)Nature Communications (3 papers)PLoS ONE (2 papers)Signal Transduction and Targeted Therapy (2 papers)
- Partner nations
- ChinaUnited StatesUnited Kingdom
In The Last Decade
Dexi Bi
48 papers receiving 2.7k citations
Dexi Bi's Hit Papers
Peers
Comparison fields: 5 of 128
- Molecular Medicine 526
- Endocrinology 337
- Microbiology 94
- Molecular Biology 1.0k
- Infectious Diseases 266
Countries citing papers authored by Dexi Bi
This map shows the geographic impact of Dexi Bi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dexi Bi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dexi Bi more than expected).
Fields of papers citing papers by Dexi Bi
This network shows the impact of papers produced by Dexi Bi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dexi Bi. The network helps show where Dexi Bi may publish in the future.
Co-authors
The 25 scholars most cited alongside Dexi Bi, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 51 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | ICEberg 2.0: an updated database of bacterial integrative and conjugative elements Hit paper breakdown → | 2018 | 357 |
| 2 | Ketogenic diet for human diseases: the underlying mechanisms and potential for clinical implementations Hit paper breakdown → | 2022 | 260 |
| 3 | 2019 | 222 | |
| 4 | Fusobacterium nucleatum enhances the efficacy of PD-L1 blockade in colorectal cancer Hit paper breakdown → | 2021 | 213 |
| 5 | 2010 | 212 | |
| 6 | 2011 | 171 | |
| 7 | 2012 | 150 | |
| 8 | 2012 | 94 | |
| 9 | 2019 | 92 | |
| 10 | 2012 | 89 | |
| 11 | 2017 | 78 | |
| 12 | 2019 | 60 | |
| 13 | 2024 | 55 | |
| 14 | 2015 | 49 | |
| 15 | 2012 | 48 | |
| 16 | 2019 | 39 | |
| 17 | 2024 | 37 | |
| 18 | 2014 | 36 | |
| 19 | 2023 | 34 | |
| 20 | 2018 | 33 |
About Dexi Bi
Dexi Bi is a scholar working on Molecular Biology, Molecular Medicine, Infectious Diseases, Ecology and Genetics, having authored 51 papers that have together received 2.7k indexed citations. Recurring topics across this work include Antibiotic Resistance in Bacteria (9 papers), Gut microbiota and health (8 papers), Bacterial Genetics and Biotechnology (6 papers), Genomics and Phylogenetic Studies (6 papers), Bacteriophages and microbial interactions (6 papers), Vibrio bacteria research studies (5 papers), Clostridium difficile and Clostridium perfringens research (4 papers) and Mycobacterium research and diagnosis (4 papers). The work is most often cited by research in Molecular Medicine (526 citations), Endocrinology (337 citations), Microbiology (94 citations), Molecular Biology (1.0k citations) and Infectious Diseases (266 citations). Dexi Bi has collaborated with scholars based in China, United States and United Kingdom. Frequent co-authors include Hong‐Yu Ou, Cui Tai, Zixin Deng, Kumar Rajakumar, Yingzhou Xie, Huiyuan Zhu, Xinyi He, Ewan M. Harrison, Huanlong Qin and Qing Wei. Their work appears in journals such as Nucleic Acids Research, Antimicrobial Agents and Chemotherapy, Nature Communications, PLoS ONE and Signal Transduction and Targeted Therapy.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.